Creative Medical Tech Enters Material Agreement, Files 8-K
Ticker: CELZ · Form: 8-K · Filed: Oct 31, 2025 · CIK: 1187953
Sentiment: neutral
Topics: material-agreement, equity-sale, financial-statements
Related Tickers: CMED
TL;DR
CMED signed a big deal and sold stock, filing an 8-K on Oct 29, 2025.
AI Summary
Creative Medical Technology Holdings, Inc. entered into a material definitive agreement on October 29, 2025. The company also reported unregistered sales of equity securities and filed financial statements and exhibits. The filing details are for the period ending October 29, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity sales, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and regulatory risks.
Key Players & Entities
- Creative Medical Technology Holdings, Inc. (company) — Registrant
- October 29, 2025 (date) — Date of earliest event reported
- 211 E Osborn Road, Phoenix, AZ 85012 (address) — Principal executive offices
- 480-399-2822 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Creative Medical Technology Holdings, Inc.?
The filing does not specify the details of the material definitive agreement, only that one was entered into on October 29, 2025.
What was the purpose of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities but does not provide details on the purpose or the amount of securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 29, 2025.
What is the principal executive office address for Creative Medical Technology Holdings, Inc.?
The principal executive office address is 211 E Osborn Road, Phoenix, AZ 85012.
What is the SIC code for Creative Medical Technology Holdings, Inc.?
The Standard Industrial Classification (SIC) code for Creative Medical Technology Holdings, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 1,020 words · 4 min read · ~3 pages · Grade level 12.8 · Accepted 2025-10-31 16:05:42
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CELZ The Nasdaq Stock Mar
- $3.75 — ants at their current exercise price of $3.75 per share, in exchange for the Company'
- $4.2 m — Existing Warrants will be approximately $4.2 million, before deducting financial advis
- $4.73 — issued in May 2022 and December 2021 to $4.73 per share, and (ii) issue warrants to p
- $40,000 — and (ii) reimburse Roth an aggregate of $40,000 for its legal expenses. The foregoing
Filing Documents
- celz_8k.htm (8-K) — 28KB
- celz_ex41.htm (EX-4.1) — 116KB
- celz_ex101.htm (EX-10.1) — 48KB
- 0001477932-25-007849.txt ( ) — 346KB
- celz-20251029.xsd (EX-101.SCH) — 5KB
- celz-20251029_lab.xml (EX-101.LAB) — 14KB
- celz-20251029_cal.xml (EX-101.CAL) — 1KB
- celz-20251029_pre.xml (EX-101.PRE) — 9KB
- celz-20251029_def.xml (EX-101.DEF) — 2KB
- celz_8k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On October 29, 2025, Creative Medical Technology Holdings, Inc. (the "Company") entered into warrant exercise inducement offer letters (the "Inducement Letters") with the holders (the "Holders") of warrants to purchase an aggregate of 1,116,136 shares of the Company's common stock originally issued on March 6, 2025 (collectively, the "Existing Warrants"), pursuant to which the Holders agreed to exercise the Existing Warrants at their current exercise price of $3.75 per share, in exchange for the Company's agreement to issue the Holders new warrants to purchase an aggregate of 2,790,340 shares of common stock (the "Inducement Warrants"). The aggregate gross proceeds from the exercise of the Existing Warrants will be approximately $4.2 million, before deducting financial advisory fees. The net proceeds received by the Company will be used for working capital and general corporate purposes. The shares of common stock issuable upon exercise of the Existing Warrants are registered for issuance pursuant to a registration statement on Form S-3 (File No. 333-286346), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 11, 2025. In consideration for the cash exercise of the Existing Warrants, the Holders were issued the Inducement Warrants in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The Inducement Warrants have an exercise price of $3.75 per share, subject to the reduction of such exercise price to the lowest "VWAP" of the Company's common stock on any trading day during the five trading day period commencing on the issuance date of the Inducement Warrants. The Inducement Warrants will not be exercisable until the Company has obtained stockholder approval for the issuance of the shares of common stock underlying the Inducement Warrants as required by the applicable rules and regulations of the Nasdaq Stoc
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. The disclosure in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . 4.1 Form of Inducement Warrant 10.1 Form of Inducement Letter 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Creative Medical Technology Holdings, Inc. Date: October 31, 2025 By: /s/ Timothy Warbington Timothy Warbington, Chief Executive Officer 3